2018 News Releases

Keyword Search
 
DateTitle  
06/08/18Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif., June 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on June 7, 2018, the company granted inducement awards to 24 new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acc... 
 Printer Friendly Version
05/30/18Dermira to Present at Jefferies 2018 Global Healthcare Conference
MENLO PARK, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at the Jefferies 2018 Global Healthcare Conference. Location: New York, NY Presentation date: Wednesday, June 6, 2018 Prese... 
 Printer Friendly Version
05/14/18Dermira to Host Analyst & Investor Day on May 24, 2018
MENLO PARK, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, will host a live webcast in conjunction with its Analyst & Investor Day to be held in New York City on Thursday May 24, 2018 from 8:30 a.m. ET and 11:30 a.m. The event will include an overview of hyperhidrosis... 
 Printer Friendly Version
05/08/18Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on May 7, 2018, the company granted inducement awards to 11 new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ accep... 
 Printer Friendly Version
05/03/18Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update 
FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018 Lebrikizumab Phase 2b study enrolling patients, data expected in first half of 2019 MENLO PARK, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today reported financial results for ... 
 Printer Friendly Version
05/02/18Dermira and Cameran Eubanks Team Up to Raise Awareness of Excessive Sweating for the 15 Million People Living with the Condition in the U.S.
Dermira and Cameran Eubanks Team Up To Raise Awareness of Excessive Sweating ... 
 Printer Friendly Version
05/01/18Dermira to Present at Deutsche Bank 43rd Annual Healthcare Conference
MENLO PARK, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at the Deutsche Bank 43rd Annual Healthcare Conference. Location: Boston, MA Presentation date: Tuesday, May 8, 2018 Presen... 
 Printer Friendly Version
04/19/18Christopher Horan Joins Dermira as Chief Technical Operations Officer
Previously served as Senior Vice President, Global Product and Supply Chain Management at Genentech, Inc. (Roche) Brings more than 25 years of biopharma operations experience to Dermira    MENLO PARK, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the... 
 Printer Friendly Version
04/11/18Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on April 9, 2018, the company granted inducement awards to 12 new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ a... 
 Printer Friendly Version
03/20/18Dermira to Present at 17th Annual Needham Healthcare Conference
MENLO PARK, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at the 17th Annual Needham Healthcare Conference. Location: New York, NY Presentation date: Tuesday, March 27, 2018 Prese... 
 Printer Friendly Version
03/08/18Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on March 7, 2018, the company granted inducement awards to 13 new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ a... 
 Printer Friendly Version
03/08/18Dermira to Present at Cowen & Company 38th Annual Healthcare Conference
MENLO PARK, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at the Cowen & Company 38th Annual Healthcare Conference. Location: Boston, MA Presentation date: Wednesday, March 14, 201... 
 Printer Friendly Version
03/05/18Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
Company expects to discontinue the program Conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT         MENLO PARK, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to delivering new therapies to patients living with chronic skin conditions, today announced that the investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints in its two Phase 3 pivotal trials (CLAREOS-1 an... 
 Printer Friendly Version
02/22/18Dermira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Olumacostat glasaretil topline Phase 3 data expected Q1 2018 FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018 Lebrikizumab Phase 2b study enrolling patients and data expected H1 2019 MENLO PARK, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic sk... 
 Printer Friendly Version
02/17/18New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology
SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today presented new findings from its glycopyrronium tosylate (formerly DRM04) Phase 3 clinical program. The data showed that when applied topically, the investigational therapy improved disease severity, reduced sweat produ... 
 Printer Friendly Version
02/12/18Dermira Showcases Commitment to Hyperhidrosis Education and Treatment at Leading Dermatology Conference
MENLO PARK, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that new findings from its Phase 3 glycopyrronium tosylate (formerly DRM04) clinical program will be highlighted at the 76th Annual Meeting of the American Academy of Dermatology (AAD), taking place ... 
 Printer Friendly Version
02/09/18Dermira to Present at Leerink Partners 7th Annual Global Healthcare Conference
MENLO PARK, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at the Leerink Partners 7th Annual Global Healthcare Conference on Thursday February 15, 2018 at 11:30 a.m. ET. A live audio webcast... 
 Printer Friendly Version
02/08/18Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on February 7, 2018, the company granted inducement awards to 16 new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’... 
 Printer Friendly Version
01/31/18Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Study expected to enroll approximately 275 patients Topline results expected in the first half of 2019 TREBLE Phase 2 proof-of-concept results published in the Journal of the American Academy of Dermatology MENLO PARK, Calif., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditio... 
 Printer Friendly Version